Research and Markets : Urinary Incontinence Who Will Control This Market?
Research and Markets (researchandmarkets. com/reports/c14726) has announced the addition of Urinary Incontinence: Major Milestones to their offering.
Dublin (PRWEB) March 31, 2005
Research and Markets (http://www. researchandmarkets. com/reports/c14726 (http://www. researchandmarkets. com/reports/c14726)) has announced the addition of Urinary Incontinence: Major Milestones to their offering.
Urinary incontinence has three main subtypes including stress, urge and mixed, and is estimated to affect 100 million women in the seven major markets. Drug therapy for urinary incontinence has focused on overactive bladder, worth over $1.3 billion in 2003. Lilly/BI's Yentreve, launched in 2004, is the first drug treatment for stress incontinence, the most prevalent subtype of the condition.
The UI market was worth $1.3 billion in 2003 with sales dominated by leading overactive bladder drugs including Detrol (Pfizer) and oxybutynin in its various forms. New drug launches in OAB Vesicare (Yamanouchi) and Enablex (Novartis) could usurp Pfizer's dominance, while Yentreve will open up a new and underserved segment and driving growth.
The scope of this report included in-depth primary research interviews with key opinion leaders from the US and Europe to add insight on market developments and unmet needs. Opinion leaders have identified a number of unmet needs in the urinary incontinence market, particularly the need for greater support for health professionals in terms of differentiating, diagnosing and treating UI subtypes in the long term and the need for greater disease awareness both among patients and physicians.
Analysis of recent market events are also mentioned including new drug launches and impact on the market.
Secondary resources include IMS MIDAS sales and promotional data across the seven major markets, IDdb, IMS R&D Focus, Medline.
Reasons to Read this report:
-Understand barriers to treatment in the female UI population including obstacles in help-seeking behavior and difficulties in the diagnostic pathway.
-Identify physicians key concerns in urinary incontinence including unmet needs and desirable attributes of novel drugs for Overactive Bladder.
-Evaluate new drugs entering the market including key efficacy and safety trial data and their potential impact on the market.
Overview of Urinary Incontinence from the following perspectives:
-epidemiology
-etiology
-definitions and subtypes
-therapeutic strategies
-pipeline products
-unmet needs
-impact of recent market events including first global launch of marketed product for stress incontinence
For more information visit http://www. researchandmarkets. com/reports/c14726 (http://www. researchandmarkets. com/reports/c14726)
Laura Wood
Senior Manager
Research and Markets
Press@researchandmarkets. com
Fax: +353 1 4100 980
###
.jpg)